conclusions there was no significant difference in the efficacy of peginterferon-alpha-2a and peginterferon-alpha-2b in iranian patients. physicians might choose the treatment regimen for every individual concerning the differences in side effects of peginterferons. background nearly 0.5% of iranians are infected with hcv. peginterferon-alpha-2a and peginterferon-alpha-2b are the two available ...

Chronic hepatitis B virus (HBV) is a serious and life-threatening disease afflicting 350 million of the world's population. So far, current monotherapy with conventional interferon-alpha, lamivudine, and adefovir dipivoxil remains unsatisfactory. In addition, the use of conventional interferon-alpha needs to be administered subcutaneously daily or thrice weekly and is associated with frequent a...

introduction various types of dermatological manifestations have been reported due to hepatitis c virus (hcv) infection and anti­hcv therapy. some of them have been described during ifn-based therapies. peg-ifn-α-2a/rbv combination is used as the international standard of treatment for hcv infection for a long time. the combination therapy yields an adverse-event profile similar to standard int...

BACKGROUND The role of nitric oxide (NO) in infectious diseases is gaining attention because of its antiviral effects. AIM To evaluate whether serum and hepatic NO levels are predictors of the outcome of treatment in patients with chronic hepatitis C genotype 4. METHODS Fifty six patients with chronic HCV genotype 4 treated with pegylated interferon (IFN) alpha-2a plus ribavirin underwent b...

Indian kala-azar patients have normal numbers of peripheral blood NK cells but impaired functional activity due to decreased binding and lysis of target cells. This impairment of NK activity could not be corrected by exogenous recombinant human alpha or gamma interferon. However, recombinant human interleukin 2 was able to restore this activity by augmenting conjugate formation and lysis of tar...

OBJECTIVE To review and compare side effects of hepatitis C treatment with pegylated interferon and ribavirin at the CRIE of the Hospital Mário Covas (Santo André), São Paulo, Brazil, from February 23 to May 5, 2011. METHODS Cross-sectional study through questionnaire, with a non-probability sample comprised of 340 patients that had received at least one dose of the medication. RESULTS Side...